Novartis is aiming for its annual sales to grow in the high single digits this year when it previously estimated they would grow in the mid-single...
Novartis has stated that it is focused on five therapeutic areas, including cardiovascular, immunology, and neuroscience. By markets, the company has detailed that it plans to...
Thanks to this investment plan, Novartis Italia, which already achieved a turnover of €1.72 billion in 2022, €78 million of which was obtained through exports, further...
This year, one of the main headaches for managers in the sector will be inflation. GSK and Novartis plan to carry out a double-digit price increase...
Novartis has the worst rating in the European pharmaceutical industry, while AstraZeneca downgrades its expectations from exceptional to neutral. Credit Suisse has also analyzed the Spanish...
The Swiss pharmaceutical company plans to lay off 8,000 workers worldwide, equivalent to 7.7% of the total workforce. The Novartis job cuts are part of the...